Janssen gets pri­or­i­ty re­view for prostate can­cer com­bo; Im­muno­Gen re­ports Q1 Ela­here sales

Janssen’s com­bi­na­tion ther­a­py of ni­ra­parib with abi­raterone ac­etate plus pred­nisone for the treat­ment of BCRA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) is mov­ing along.

Jannsen post­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.